Turbocharging Your Next Gen LNP End-To-End Development to Deliver Curative Promises to Patients Following exciting industry updates from Verve Therapeutics’ GalNAc-LNP for PCSK9 for HFpEF treatment, to Recode’s 5th element, […]

The field of FcRn receptor targeting is gaining ground-breaking speed as Argenx, Janssen, UCB and Immunovant compete to tackle myasthenia gravis and biopharma invest in transformative immunological therapy for autoimmune […]

mRNA therapeutics have catapulted into the limelight amidst the COVID-19 pandemic with multiple EMA approvals to help combat the virus. Bringing together KOLs sharing case studies with actionable insights, the […]